購読する
モデル製品
サービス
前臨床薬効評価
コミュ二ティー
NKG-H11-hB2M&HLA-A2.1 Mouse
製品のお見積りを依頼する
当社のカタログから製品を選択してご注文ください。当社チームが詳細な情報をご連絡いたします。
NKG-H11-hB2M&HLA-A2.1 Mouse
製品名
NKG-H11-hB2M&HLA-A2.1 Mouse
製品ID
C001844
系統名
NOD.Cg-PrkdcscidIl2rgem1cyaIgs2em1(B2M/HLA-A2.1/H2-D1)/Cya
背景情報
NKG
状況
このマウス系統を論文で使用する場合は、「NKG-H11-hB2M&HLA-A2.1 Mouse(カタログ番号C001844)はサイアジェンから購入しました。」と引用してください。
Immunodeficient Mice
Safe Harbor Knock-in
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
お見積もりについてはこちらまでご連絡ください
Immunodeficient Mice
Safe Harbor Knock-in
基本情報
関連リソース
基本情報
遺伝子別名
IMD43, HLAA, gc, p64, [g]c, CD132, gamma(c)
染色体
Chr 15, Chr 6, Chr X
MGI ID
さらに
系統詳細
NKG mice are a type of severe immunodeficient mouse developed by Cyagen by deleting the Il2rg gene from the NOD-Scid strain. This strain lacks mature T, B, and NK cells, exhibits reduced complement activity, and weak macrophage phagocytosis of human cells. As a result, NKG mice can efficiently engraft human hematopoietic stem cells (HSC), peripheral blood mononuclear cells (PBMC), patient-derived xenografts (PDX), or adult stem cells and tissues.
In immunology research, direct studies on mice may not fully represent the human immune system due to physiological and immune system differences. However, by transplanting human peripheral blood mononuclear cells (PBMCs) or hematopoietic stem cells (HSCs) into immunodeficient mice, we can partially or completely replace the mouse immune system with a human counterpart. This approach enables in vivo simulation of human immune system function, providing an effective model for studying human immunity. However, in actual human-mouse xenotransplantation, due to the lack of specific human cytokines and supportive stromal cells in mice, transplantation using conventional immunodeficient mice is likely to result in variations in immune reconstitution efficiency. Modifying immunodeficient mice via gene editing technology to establish a humanized immune microenvironment in mice and promote the functional maturation of human-derived cells is a universal strategy for improving the efficiency of immune reconstitution in xenotransplantation.
The B2M gene encodes beta-2 microglobulin, a serum protein on the surface of nearly all nucleated cells along with the major histocompatibility complex (MHC) class I heavy chain. It is an essential component for transporting MHC class I proteins to the cell surface. Human leukocyte antigen (HLA), or the major histocompatibility complex (MHC), is a group of protein molecules on the surface of antigen-presenting cells responsible for antigen presentation. HLA mainly includes HLA class I, HLA class II, and HLA class III. HLA class I molecules (such as HLA-A, HLA-B, and HLA-C) primarily present antigens to CD8+ T cells and play a central role in the immune system. Through antigen presentation by HLA class I, the body can effectively recognize abnormal peptides, triggering targeted immune responses for immune clearance. Studies have shown that peptide vaccines composed of covalently linked minimal cytotoxic T lymphocyte (CTL) and T helper cell (TH) epitopes have significant effects in inducing cellular immune responses [1]. Due to species differences between mice and humans, and the varying ability of different HLA molecule subtypes to present different antigens, mouse-derived HLA cannot effectively simulate the immune response of human HLA subtypes. Therefore, constructing mice carrying human HLA genes helps to advance the study of HLA-restricted cytotoxic responses, such as identifying immunodominant HLA-restricted CTL epitopes and optimizing DNA vaccine constructs for human use [2-3].
NKG-H11-hB2M&HLA-A2.1 mouse is a model constructed via gene editing technology, in which the H2-K1 chimeric HLA-A2.1 gene is knocked into the H11 locus of mice on the NKG strain background. Compared with NKG mice, NKG-H11-hB2M&HLA-A2.1 mice generate functional human T cell subsets with HLA-restricted immune responses after hematopoietic stem cell (HSC) transplantation. Human cytotoxic T lymphocytes (CTLs) developed in immunologically reconstituted mice recognize pathogens in an HLA-restricted manner and exert HLA-restricted cytotoxicity against infected human B cells [4]. This model provides an ideal platform for investigating human immune responses to pathogens, HLA-restricted cytotoxic responses, and related research areas.
参考文献
La Rosa C, Wang Z, Brewer JC, Lacey SF, Villacres MC, Sharan R, Krishnan R, Crooks M, Markel S, Maas R, Diamond DJ. Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice. Blood. 2002 Nov 15;100(10):3681-9.
Gotoh M, Takasu H, Harada K, Yamaoka T. Development of HLA-A2402/K(b) transgenic mice. Int J Cancer. 2002 Aug 10;100(5):565-70.
Boucherma R, Kridane-Miledi H, Bouziat R, Rasmussen M, Gatard T, Langa-Vives F, Lemercier B, Lim A, Bérard M, Benmohamed L, Buus S, Rooke R, Lemonnier FA. HLA-A*01:03, HLA-A*24:02, HLA-B*08:01, HLA-B*27:05, HLA-B*35:01, HLA-B*44:02, and HLA-C*07:01 monochain transgenic/H-2 class I null mice: novel versatile preclinical models of human T cell responses. J Immunol. 2013 Jul 15;191(2):583-93.
Shultz LD, Saito Y, Najima Y, Tanaka S, Ochi T, Tomizawa M, Doi T, Sone A, Suzuki N, Fujiwara H, Yasukawa M, Ishikawa F. Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD/SCID/IL2r gamma(null) humanized mice. Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13022-7.
系統作製戦略
The Mouse K2-K1 promoter-Kozak-HLA-A2.1 leader sequence - Human Mature B2M CDS-3xGGGGS-Chimeric-HLA-A2.1 (HLA-A2.1 alpha1 and alpha2 binding domains-H2-D1 alpha3, cytoplasmic and transmembrane domains)-H2-D1 3'sequence cassette was inserted into H11 locus.

Figure 1. Gene editing strategy of NKG-H11-hB2M&HLA-A2.1 mice.
適用分野
Construction of immune system humanized mouse models;
Research on the human immune system and hematopoietic system;
Research on HLA-restricted cytotoxic responses, research on human viral infectious diseases, and development and testing of novel viral vaccines;
Research on oncology and autoimmune diseases;
Cell line-derived xenograft (CDX) and drug screening and efficacy evaluation;
Patient-derived xenograft (PDX) and drug screening and efficacy evaluation.
関連リソース
お問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
